General Updates

GUJARAT THEMIS BIOSYN LIMITED CIN: L24230GJ1981PLC004878 REGD. OFFICE &FACTORY : 69/C GIDC INDUSTRIAL ESTATE, VAPI – 396 195, DIST. VALSAD, GUJARAT, INDIA TEL : 0260-2430027 / 2400639 E-mail:hrm@gtbl.in.net 18th September, 2026 Listing Department Department of Corporate Services National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block-G Phiroze Jeejeebhoy Towers, Dalal Street Bandra Kurla Complex Mumbai 400001 Bandra East, Mumbai 400051 Symbol: GUJTHEM Scrip Code: 506879 Dear Sir / Madam, Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we hereby update you that Gujarat Themis Biosyn Limited (GTBL or Company) has completed the acquisition of MicroBiopharm Japan Co., Ltd. (MBJ), Japan, through its wholly owned subsidiary, Themis Biosyn Japan Limited (TBJ), by making an investment of INR 475 Crores towards capital contribution and INR 745 Crores by way of loan in TBJ. In this regard GTBL has entered into a Loan agreement with TBJ for an amount upto INR 800 Crores on the terms as may be agreed. Details of the agreement are given in annexure 1 attached herewith. We further update you that all customary closing conditions and requisite regulatory and other formalities in relation to the above acquisition have been fulfilled and the transaction has been completed. A Press release in this respect is attached herewith The above disclosure is being made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This is for your information and records. Thanking you Yours faithfully For Gujarat Themis Biosyn Limited Vineet Gawankar Company Secretary & Compliance Officer Encl.: As above MUMBAI OFFICE: Themis House, 11/12 Udyog Nagar, S.V Road, Goregaon (West), Mumbai – 400 104 Tel .: 91-22-67607080 / 28757836 Fax : 28746621 / 67607019 E-mail : gtblmumbai@gtbl.inWebsite Address : www.gtbl.in PRESS RELEASE Gujarat Themis Biosyn Ltd. completes acquisition of Japan-based MicroBiopharm Japan Co., Ltd. Acquisition to boost Company’s fermentation capabilities, product portfolio and geographical footprint Mumbai, September 18, 2026: Gujarat Themis Biosyn Limited (“GTBL” or the “Company”) (BSE: 506879, NSE: GUJTHEM), today announced the completion of the acquisition of 100% equity shareholding in MicroBiopharm Japan Co., Ltd. (“MBJ”), Japan, through Themis Biosyn Japan Limited, a wholly owned subsidiary incorporated in Japan. The transaction, first announced on May 22, 2026, has now been closed following receipt of all customary regulatory approvals and satisfaction of closing conditions. The acquisition was made from funds managed or advised by T Capital Partners Co., Ltd., a Japan- based private equity fund, for a total consideration of JPY 21.5 billion, funded through an optimal mix of debt and equity. The transaction is expected to be EPS accretive for GTBL. The existing MBJ management team will continue to lead operations. With over 60 years of experience, MBJ operates three GMP-compliant manufacturing plants with a strong FDA and PMDA inspection track record. For FY26, MBJ has registered revenue of JPY 9.5 billion ,with a business mix spanning Proprietary APIs/Intermediates, CDMO, CDMO Bio and Developed Pharmaceuticals (bio)/Non-Pharma. The company has serviced its top six customers for over two decades, with approximately 40% of its revenue generated from outside Japan. Strategic Rationale and Synergies: The acquisition accelerates GTBL's transition towards becoming a fermentation-based, globally integrated CDMO, and is expected to deliver the following key benefits: ● Precision Fermentation & Enzyme-based bioconversion platforms: Entry into precision fermentation through MBJ's proprietary P450 enzyme library (hydroxylation) and thereby reducing reliance on traditional chemical routes. ● Proprietary Products – APIs: Supply of API/Intermediates for Oncology, Immunosuppressants, Peptides and Antibiotics to leading global pharma companies, including Big Pharma, broadening GTBL's product depth and revenue diversification. ● Advanced Biologics & Novel Modalities: Access to Plasmid DNA, ADC conjugation, and recombinant protein technologies, positioning the combined platform in high-growth, innovation-led pharmaceutical segments. ● Precision Fermentation: Entry into precision fermentation through MBJ's proprietary P450 enzyme library (hydroxylation), complementing GTBL's existing fermentation strengths and reducing reliance on traditional chemical routes. ● Scalable, Regulated Manufacturing Footprint: Three GMP-compliant sites with strong FDA and PMDA inspection track records, enabling expanded access to regulated global markets and a fully integrated CDMO platform spanning discovery, development and commercial manufacturing. ● Diversified Global Revenue Base & Big Pharma Access: ~40% of MBJ's revenues are generated from outside Japan, backed by long-standing relationships with blue-chip pharma customers across Asia, Europe and North America – enabling cross-selling and accelerated market penetration. ● India Cost Advantage for Margin Expansion: Opportunity to leverage GTBL's India manufacturing scale to improve cost competitiveness and drive margin expansion on high- value products. Commenting on the completion of the acquisition, Dr. Sachin Patel, Managing Director, Gujarat Themis Biosyn Limited, said, “The successful completion of this acquisition marks a defining milestone in GTBL's journey towards becoming a fermentation-based, globally integrated CDMO. MBJ brings to us over six decades of fermentation expertise, a proprietary P450 enzyme platform, and deep, long-standing relationships with leading global pharmaceutical companies. Together, we are well placed to expand our presence across various avenues including oncology, immunosuppressants, peptides and advanced biologics, while leveraging GTBL's India manufacturing scale to drive growth. We warmly welcome the MBJ team, who will continue to lead operations, and look forward to building this platform together for a mutually rewarding journey ahead.” Commenting on the completion of the acquisition, Mr. Shiota, CEO, MicroBiopharm Japan Co., Ltd , said, “This acquisition paves the way for a mutually rewarding journey, combining MBJ's precision fermentation capabilities, biotechnology platforms, and strong relationships with leading pharmaceutical companies, with GTBL's long-standing expertise in fermentation technology, large- scale manufacturing capabilities, and broad portfolio. Together, these complementary strengths will enable us to create greater value and, as part of the Themis Group, grow into a leading CDMO with a strong global footprint.” Deloitte India acted as an exclusive Financial advisor to GTBL , Tokyo International Law Office (TKI) Japan served as legal counsel and Avendus Capital acted as the exclusive financing arranger to GTBL on this transaction. About Gujarat Themis Biosyn Limited: GTBL is an India-based pharmaceutical company engaged in the development, manufacturing and marketing of fermentation-based pharmaceutical intermediates and APIs across key therapeutic segments in India. The company specializes in fermentation-based product development and continues to expand its presence across the Indian and global markets with a focus on building an integrated and scalable pharmaceutical platform. https://www.gtbl.in/ About MicroBiopharm Japan Co., Ltd.: MBJ is a Japan-based pharmaceutical company engaged in the research, development, and manufacturing of APIs, intermediates, and contract development and manufacturing (CDMO) services. The company has established strong capabilities in microbial fermentation and biotechnology-based manufacturing and offers a diversified portfolio spanning oncology APIs, vitamin D derivativ [Showing first 8,000 characters — download PDF for full document]